Inhalat (Salbutamol Sulfate)

Salbutamol sulfate is a short‑acting beta2‑adrenergic receptor agonist. By binding to beta2 receptors on bronchial smooth muscle, it activates adenylate cyclase, increasing intracellular cyclic AMP. Elevated cAMP leads to relaxation of the smooth‑muscle fibers, producing bronchodilation and improved airflow within minutes of inhalation.

The specific dose of Inhalat is determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. The prescriber selects the number of inhalations and frequency that best manage symptoms, and patients should follow the written instructions without deviation.

Safety data for salbutamol sulfate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers weigh potential benefits against risks before prescribing to pregnant or nursing women, and the decision should be individualized.

To request Inhalat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature control), and assistance with import documentation.

Inhalat contains salbutamol, a short‑acting beta2‑agonist that provides rapid onset of action, typically within minutes, and a duration of 4–6 hours. Compared with long‑acting agents such as formoterol or salmeterol, it is intended for rescue use rather than maintenance therapy, and its safety profile reflects the class‑wide effects of beta2‑agonists.

Inhalat should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. The inhaler device should be kept upright, and the mouthpiece cleaned regularly according to the manufacturer’s instructions to maintain dose accuracy.

Inhalat is delivered via a handheld inhaler device. The patient exhales fully, places the mouthpiece in the mouth, and actuates the device while inhaling slowly and deeply. After holding the breath for a few seconds, the patient can exhale. The prescribed number of puffs is taken as directed by the prescriber.

Although uncommon, serious adverse events can occur with Inhalat. These include paradoxical bronchospasm, which worsens breathing; significant cardiac arrhythmias or tachycardia; severe hypokalemia; and hypersensitivity reactions such as anaphylaxis. Patients experiencing these symptoms should seek immediate medical attention.

Inhalat is contraindicated in individuals with known hypersensitivity to salbutamol sulfate or any component of the inhaler. Caution is advised for patients with severe cardiovascular disorders, uncontrolled hyperthyroidism, or those receiving non‑selective beta‑blockers, as the drug may exacerbate these conditions. Use only under medical supervision.